Fibromyalgia Overlap in Psoriatic Arthritis Complicates Disease Assessment
Fibromyalgia frequently coexists with psoriatic arthritis (PsA), significantly complicating diagnosis and management, according to a recent narrative review. The analysis highlights that fibromyalgia symptoms can inflate disease activity scores in PsA, potentially leading to misinterpretation of inflammatory burden. The findings underscore the need for more precise assessment tools and tailored management strategies in patients with overlapping conditions.
Study Findings
Substantial variability exists across studies of PsA coexisting with fibromyalgia, ranging from an estimated 18% to 64% of patients with PsA. Patients with this overlap consistently demonstrate higher scores for pain, tenderness, fatigue, sleep disturbance, and cognitive dysfunction compared with those with PsA alone.
Importantly, standard PsA disease activity indices—commonly used to guide treatment—may be skewed in the presence of fibromyalgia. These measures often capture symptoms of central sensitization rather than true inflammatory activity. As a result, clinicians may overestimate disease severity and escalate treatment unnecessarily, including the use of disease-modifying antirheumatic drugs (DMARDs).
The authors note that fibromyalgia exists along a continuum, with many patients exhibiting subthreshold symptoms that still impair quality of life and functional status. Tools such as the Fibromyalgia Impact Questionnaire and the Polysymptomatic Distress Scale can help differentiate fibromyalgia-related symptoms from inflammatory joint and tendon pathology characteristic of PsA.
Mechanistically, both peripheral and central pain pathways contribute to fibromyalgia in PsA. Factors such as obesity, cumulative disease burden, and activation of the stress response are implicated. The review frames fibromyalgia not merely as a comorbidity but as part of a broader neurobiological stress response to chronic illness.
Clinical Implications
For clinicians managing PsA, recognizing coexisting fibromyalgia is critical to avoid overtreatment and optimize patient outcomes. Elevated disease activity scores should be interpreted cautiously, particularly when clinical findings do not align with objective markers of inflammation.
Accurate differentiation between inflammatory and noninflammatory pain drivers can guide more appropriate interventions. While PsA-related inflammation may require immunomodulatory therapy, fibromyalgia symptoms often respond better to nonpharmacologic approaches, including exercise, sleep optimization, and cognitive-behavioral strategies, as well as selected pain-modulating medications.
Routine use of validated assessment tools may improve diagnostic clarity and support individualized care plans. Addressing comorbid factors such as obesity and psychological stress is also essential, given their contribution to central sensitization.
Ultimately, a multidisciplinary and nuanced approach is required, as management focused solely on inflammation may fail to address the full spectrum of patient symptoms.
Reference:
Findeisen KE, Guymer EK, Littlejohn GO. Unravelling fibromyalgia in psoriatic arthritis. Rheumatol Ther. 2026;13(2):299-311 DOI: 10.1007/s40744-026-00825-6
